- Home
- IMNM
IMNM
Immunome Inc.
as 04-18-2025 1:37pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 542.6M | IPO Year: | 2020 |
| Target Price: | $26.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $19.07 | Next Earning Date: | 05-13-2025 |
| Revenue: | $9,041,000 | Revenue Growth: | -35.50% |
| Revenue Growth (this year): | -85.5% | Revenue Growth (next year): | 1259.12% |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | IMNM | President and CEO | Mar 26 '25 | Buy | $7.29 | 137,100 | $999,459.00 | 806,736 | |
| BIENAIME JEAN JACQUES | IMNM | Director | Mar 25 '25 | Buy | $7.78 | 7,800 | $60,684.00 | 31,415 | |
| BIENAIME JEAN JACQUES | IMNM | Director | Mar 24 '25 | Buy | $8.21 | 7,000 | $57,470.00 | 31,415 | |
| Tsai Philip | IMNM | Chief Technology Officer | Mar 24 '25 | Buy | $8.42 | 12,300 | $103,566.00 | 33,300 | |
| SIEGALL CLAY B | IMNM | President and CEO | Jan 31 '25 | Buy | $7.75 | 150,000 | $1,162,500.00 | 806,736 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?
Business Wire
15 days ago
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
Business Wire
16 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
17 days ago
Clay Siegall Bought 20% More Shares In Immunome
Argus Research
23 days ago
Daily – Vickers Top Buyers & Sellers for 03/27/2025
TipRanks
23 days ago
Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement
MT Newswires
24 days ago
Immunome Insider Bought Shares Worth $999,459, According to a Recent SEC Filing
Argus Research
24 days ago
Daily – Vickers Top Buyers & Sellers for 03/26/2025
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.